Properties (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Biogen_Idec
|
| gptkbp:awards |
FDA_approval_for_Bexxar
FDA_approval_for_Rituxan FDA_approval_for_Zevalin |
| gptkbp:CEO |
George A. Scangos
Paul_J._Clancy |
| gptkbp:clinicalTrials |
ongoing
completed phases 1, 2, and 3 |
| gptkbp:founded |
1985
|
| gptkbp:founder |
Howard_W._Robin
|
| gptkbp:headCoach |
approximately 1,000 employees
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Idec Pharmaceuticals
|
| gptkbp:industry |
biotechnology
|
| gptkbp:keyPeople |
gptkb:William_H._Rastetter
George A. Scangos James_C._McNerney |
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
$5 billion (approx.)
|
| gptkbp:mayHave |
Michael A. McGowan
|
| gptkbp:notableEvent |
gptkb:Zevalin
Rituxan Bexxar |
| gptkbp:partnerships |
gptkb:Genentech
gptkb:Pfizer gptkb:Amgen AbbVie |
| gptkbp:patentCitation |
numerous patents in biotechnology
|
| gptkbp:philanthropy |
community health initiatives
support for cancer research support for autoimmune disease research |
| gptkbp:products |
monoclonal antibodies
therapeutic proteins small molecule drugs |
| gptkbp:R&D |
gptkb:San_Diego
|
| gptkbp:researchFocus |
oncology
autoimmune diseases inflammatory diseases |
| gptkbp:revenue |
$1 billion (approx.)
|
| gptkbp:specializesIn |
biopharmaceuticals
|
| gptkbp:subsidiary |
gptkb:Biogen_Idec_Inc.
Idec_Biopharmaceuticals Idec_Pharmaceuticals_Corp. |
| gptkbp:tradedOn |
gptkb:NASDAQ
gptkb:NYSE |
| gptkbp:website |
www.idecpharma.com
|